Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib in Refractory Indolent Non-Hodgkin Lymphoma
NCT01882803Phase 2Completed
- Sponsor
- Secura Bio
- Start
- Jun 2013
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of duvelisib in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Secura Bio. Started Jun 2013; status: completed.
02
Drugs
duvelisib
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT01882803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01882803.